Cerus (CERS) Stock: Buy, Sell, or Hold?
CERS - Cerus Corp
$2.29
-0.05 (-2.14%)
▼
5d:
-3.78%
30d:
-9.84%
90d:
-27.3%
HOLD
LOW Confidence
Analysis Updated: Oct 7, 2026 12:00 AM ET
Earnings: Nov 05, 2026
27d
Get Alerted When CERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CERS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CERS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CERS is currently trading at $2.29, which is considered oversold relative to its 30-day fair value range of $2.41 to $2.64. From a valuation perspective, the stock is trading at a discount (Forward PE: -458.0) compared to its historical average (76.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CERS is in a downtrend. The price is currently testing key support at $2.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CERS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.12 (+123.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CERS is in a downtrend. The price is currently testing key support at $2.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CERS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.12 (+123.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.41 -
$2.64
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 123.8% below Wall St target ($5.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 18% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.41 -
$2.64
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.25
Resistance Level
$2.63
Current Trend
Downtrend
Technical data as of
Oct 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-458.00
Wall Street Target
$5.13
(+123.8%)
Revenue Growth (YoY)
9.5%
Profit Margin
-3.1%
PE vs Historical
-458.0 vs 76.8
CHEAP
Share & Embed Analysis
Last updated: October 08, 2026 1:43 AM ET
Data refreshes hourly during market hours. Next update: 2:43 AM
Data refreshes hourly during market hours. Next update: 2:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$101 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
28 analysts |
$95 | 46 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$121 | 55 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
28 analysts |
$368 | 53 HOLD |
|
TNDM
Tandem Diabetes Care Inc |
BUY
24 analysts |
$28 | 67 BUY |
